The popularity of Sildenafil initially fueled a period of growth for major pharmaceutical companies, however recent changes present a uncertain scenario for shareholders. Generic alternatives are eating into profits, https://loriskji480028.tinyblogging.com/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet-85338487